Chemotherapy-induced anemia (CIA)
In anemic cancer patients with non-myeloid malignancies receiving myelosuppressive chemotherapy
divider
Expected rise in Hb starting at Week 41
Expected rise in Hb starting at Week 4
Study design
A randomized, double-blind, placebo-controlled, 16-week clinical study in 344 patients with anemia receiving concomitant chemotherapy for cancer. Patients received PROCRIT® 40,000 U (n=174) or placebo (n=170) SC weekly for 16 weeks.1,2

  • Patients receiving PROCRIT® had a significant increase in Hb compared with patients receiving placebo starting at Week 4 and through the rest of the study (Week 16) (P<0.001)1
  • Over the course of the study, 73% of patients receiving PROCRIT® achieved a ≥2 g/dL increase in Hb compared with 32% of patients receiving placebo (P<0.0001)1
  • RBC transfusions and/or PROCRIT® dose adjustments were permitted1
divider
Reduces the need for transfusions1,2
Reduces the need for transfusions
Study design
A randomized, double-blind, placebo-controlled, 16-week clinical study in 344 patients with anemia receiving concomitant chemotherapy for cancer. Patients received PROCRIT® 40,000 U (n=174) or placebo (n=170) SC weekly for 16 weeks.1,2
  • 28% of placebo-treated patients received transfusions, compared with 14% of PROCRIT®-treated patients (P=0.001)1,2
Maintaining Hb rise with erythropoiesis-stimulating agents (ESAs) is essential to avoiding transfusions

divider
Selected safety profile
Adverse reactions occurring in ≥5% of patients2*

Adverse reaction PROCRIT®-treated patients (n=168) Placebo-treated patients (n=165)
Nausea 35% 30%
Vomiting 20% 16%
Myalgia 10% 5%
Arthralgia 10% 6%
Stomatitis 10% 8%
Cough 9% 7%
Weight decline 9% 5%
Leukopenia 8% 7%
Bone pain 7% 4%
Rash 7% 5%
Hyperglycemia 6% 4%
Insomnia 6% 2%
Headache 5% 4%
Depression 5% 4%
Dysphagia 5% 2%
Hypokalemia 5% 3%
Thrombosis 5% 3%
  • From a double-blind, placebo-controlled, 16-week study with 333 cancer patients with anemia due to chemotherapy2
*Adverse reactions with a reported incidence of ≥5% in PROCRIT®-treated patients that occurred at a higher frequency than in placebo-treated patients.2
divider

References
  1. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol. 2005;23:2606-2617.
  2. PROCRIT (epoetin alfa) Prescribing Information. Janssen Products, LP.
 
Indications and Important Safety Information
EXPAND    Expand ISI
Indications
Expand ISI
Important Safety Information
Expand ISI